BioMarin Pharmaceutical Inc. (BMRN) stock is down -35.44% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives BMRN stock a score of 27 out of a possible 100. That rank is influenced by a short-term technical score of 12. BMRN's rank also includes a fundamental score of 26. In addition to the average rating from Wall Street analysts, BMRN stock has a mean target price of $106.20. This means analysts expect the stock to gain 37.28% over the next 12 months. The long-term technical score for BMRN is 43.
BioMarin Pharmaceutical Inc. (BMRN) Stock Declines -1.46% This Week; Should You Buy?
BMRN has an Overall Score of 27. Find out what this means to you and get the rest of the rankings on BMRN!